Alhzeimer Disease

Pathophysiology Description (Narrative)

Alzheimer’s disease is characterized by extracellular amyloid-β (Aβ) deposition, intracellular hyperphosphorylated tau aggregation, synaptic failure, neuroinflammation, proteostasis disruption in the autophagy–lysosomal system, mitochondrial/oxidative stress, and neurovascular and glymphatic clearance impairments, integrated over a long preclinical period measurable by fluid/imaging biomarkers. Contemporary frameworks increasingly treat amyloid/tau, immune, proteostatic, metabolic, and clearance mechanisms as interconnected drivers rather than isolated cascades, with biomarkers (especially phosphorylated tau) shifting earlier in the sequence and guiding clinical implementation. As a recent review notes, “Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages” and prion-like propagation of tau has become a central theme in disease spread, alongside attention to meningeal/glymphatic clearance routes (DOI: 10.3390/ijms252212311, 2024-11-16) (sighencea2024fromfundamentalsto pages 36-37, sighencea2024fromfundamentalsto pages 1-3).

Key immune–metabolic axes (APOE–TREM2) shape microglial states, with downstream inflammasome (e.g., NLRP3–ASC) signaling promoting IL‑1β–mediated neuroinflammation and synaptotoxicity. A 2024 synthesis highlights that Aβ and tau aggregates activate inflammatory signaling in microglia and astrocytes and implicates APOE (ε4 risk), TREM2 (microglial receptor), and NLRP3 inflammasomes, while also emphasizing necroptosis and other regulated cell-death pathways (DOI: 10.3390/ijms25136901, 2024-06) (singh2024comprehensiveoverviewof pages 11-12). Endolysosomal/autophagy failure (e.g., beclin‑1/VPS34 loss, impaired autophagic flux and lysosomal acidification) causes accumulation of proteotoxic species, linking proteostasis to amyloid/tau burden and neurodegeneration (singh2024comprehensiveoverviewof pages 28-28, sighencea2024fromfundamentalsto pages 20-21). Vascular/BBB dysfunction reduces Aβ efflux (LRP1), and arteriosclerotic and pericyte-mediated signaling changes are prevalent; one review notes “92% of AD patients showing cerebral arteriosclerotic changes,” with MEOX2/LRP pathways and APOE4–Cyclophilin‑A–MMP‑9 signaling tied to perfusion and barrier integrity (DOI: 10.3390/ijms252212311, 2024-11-16) (sighencea2024fromfundamentalsto pages 20-21). Metabolic/mitochondrial dysfunction and oxidative stress intersect with insulin resistance and impaired neuronal energetics, contributing to synaptic decline and cognitive impairment (singh2024comprehensiveoverviewof pages 9-11, sighencea2024fromfundamentalsto pages 36-37).

Contemporary application: anti‑amyloid monoclonal antibodies (aducanumab, lecanemab, donanemab) have moved into practice and trials as biomarker-driven disease-modifying therapies; reviews from 2024 synthesize these approvals and trials alongside evolving biomarker frameworks and multi-target strategies (sighencea2024fromfundamentalsto pages 1-3, singh2024comprehensiveoverviewof pages 28-28).

Core Pathophysiology

1) Amyloid production and clearance - Mechanism: APP cleavage by BACE1 (β-secretase) yields C99, then γ‑secretase (PSEN1/PSEN2/NCSTN/APH1) produces Aβ; imbalance of production vs clearance (LRP1-mediated BBB efflux, perivascular/glymphatic drainage) elevates Aβ burden (quote: “The cleavage of APP by β‑secretase (BACE1) generates a membrane fragment called C99 … γ‑secretase … generates insoluble Aβ peptides.”) (DOI: 10.3390/ijms25136901, 2024-06) (singh2024comprehensiveoverviewof pages 2-3, sighencea2024fromfundamentalsto pages 20-21). - Vascular/BBB: Endothelial MEOX2 downregulation and reduced LRP1 impair Aβ clearance; APOE4–Cyclophilin‑A–MMP‑9 axis in pericytes disrupts BBB, lowering CBF and exacerbating deposition (sighencea2024fromfundamentalsto pages 20-21).

2) Tau hyperphosphorylation and prion-like spread - Mechanism: Kinases (GSK‑3β, CDK5, PKA, CaMKII) hyperphosphorylate tau (MAPT), promoting aggregation and prion-like propagation across networks; p‑tau (pT181/pT217/pT231) rises preclinically (quote: “What is the evidence that tau pathology spreads through prion‑like propagation?”; “Novel tau biomarkers … rise in the initial stages”) (DOI: 10.3390/ijms252212311, 2024-11-16) (sighencea2024fromfundamentalsto pages 36-37, singh2024comprehensiveoverviewof pages 2-3).

3) Microglial responses and innate immunity (APOE, TREM2, NLRP3) - TREM2 and APOE shape disease-associated microglial (DAM) phenotypes, influencing Aβ phagocytosis and inflammatory tone. NLRP3 inflammasome assembly (with ASC/PYCARD) promotes IL‑1β/IL‑18 maturation and pyroptosis, adding to synaptic/neuronal injury (singh2024comprehensiveoverviewof pages 11-12). CD33 and ABCA7 also modulate microglial Aβ handling (singh2024comprehensiveoverviewof pages 11-12).

4) Synaptic dysfunction and biomarkers - Synapse loss best correlates with cognition; biomarker frameworks now include synaptic and glial markers (e.g., SNAP‑25, GAP‑43, YKL‑40, NfL) across CSF/plasma, supporting staging and monitoring (DOI: 10.3390/cimb47080580, 2025-07) (agnello2025fromamyloidto pages 1-2). Reviews emphasize that synaptic injury links multiple upstream mechanisms (amyloidosis, tauopathy, neuroinflammation) to clinical decline (agnello2025fromamyloidto pages 1-2, sighencea2024fromfundamentalsto pages 36-37).

5) Endolysosomal/autophagy-lysosomal dysfunction - Beclin‑1/VPS34 deficits, p62 accumulation, and defective autophagosome–lysosome fusion/acidification lead to impaired turnover of Aβ/tau cargo and neuronal pathology; “faulty autolysosome acidification causing autophagic Aβ build-up” summarizes the proteostasis deficit (DOI: 10.3390/ijms25136901, 2024-06) (singh2024comprehensiveoverviewof pages 28-28, sighencea2024fromfundamentalsto pages 20-21).

6) Mitochondrial/oxidative stress and metabolic signaling - Mitochondrial OXPHOS deficits, ROS, and brain insulin resistance (altered PI3K/AKT/mTOR, GSK‑3β signaling) drive synaptic vulnerability and tau/Aβ pathology; SGLT2 inhibitors and insulin pathway normalization are being explored preclinically/clinically (singh2024comprehensiveoverviewof pages 9-11, sighencea2024fromfundamentalsto pages 36-37).

7) Vascular and glymphatic/meningeal lymphatic clearance - Arteriosclerosis, BBB dysfunction, and impaired perivascular/glymphatic flow reduce protein clearance; meningeal lymphatics contribute to proteostasis. A 2024 review highlights BBB, LRP1-mediated efflux, and lymphatic/glymphatic routes as emerging therapeutic targets (sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).

Key Molecular Players

• Genes/Proteins (HGNC): APP, PSEN1, PSEN2 (γ‑secretase components); APOE (ε4 risk allele); TREM2 (microglial receptor); MAPT (tau); NLRP3 and ASC/PYCARD (inflammasome); LRP1 (Aβ efflux) (singh2024comprehensiveoverviewof pages 2-3, singh2024comprehensiveoverviewof pages 11-12, sighencea2024fromfundamentalsto pages 20-21).
• Chemical entities (CHEBI): Aβ; tau; IL‑1β; reactive oxygen species (ROS) (singh2024comprehensiveoverviewof pages 11-12, sighencea2024fromfundamentalsto pages 36-37).
• Cell types (CL): neurons, microglia, astrocytes, oligodendrocytes; endothelial cells and pericytes at the BBB (singh2024comprehensiveoverviewof pages 11-12, sighencea2024fromfundamentalsto pages 20-21).
• Anatomical locations (UBERON): hippocampus, cortex, BBB, perivascular spaces, meningeal lymphatics (sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).

Table: Compact ontology-aligned table of key Alzheimer’s disease entities (genes, processes, cell types, anatomy, chemicals, phenotypes) with supporting evidence pointers to the collected sources; useful for knowledge‑base annotation and rapid reference.

Biological Processes (GO terms, disrupted)

• Amyloid‑β production and clearance (GO: amyloid‑beta metabolic process; extracellular protein clearance) (singh2024comprehensiveoverviewof pages 2-3, sighencea2024fromfundamentalsto pages 20-21).
• Tau phosphorylation and prion-like propagation (GO: tau protein phosphorylation; protein aggregate propagation) (sighencea2024fromfundamentalsto pages 36-37).
• Microglial activation and inflammasome assembly (GO: microglial cell activation; inflammasome complex assembly) (singh2024comprehensiveoverviewof pages 11-12).
• Autophagy–lysosomal proteostasis (GO: autophagy; lysosomal degradation) (singh2024comprehensiveoverviewof pages 28-28, sighencea2024fromfundamentalsto pages 20-21).
• Insulin receptor signaling/glucose metabolism (GO: insulin receptor signaling pathway) (singh2024comprehensiveoverviewof pages 9-11).
• Oxidative stress and mitochondrial dysfunction (GO: response to oxidative stress) (sighencea2024fromfundamentalsto pages 36-37, singh2024comprehensiveoverviewof pages 9-11).
• Synaptic dysfunction and plasticity failure (GO: synaptic signaling/plasticity) (agnello2025fromamyloidto pages 1-2).

Cellular Components (where key processes occur)

• Extracellular space and perivascular compartments (Aβ plaques, glymphatic/perivascular clearance) (sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).
• Cytosol/axon for tau aggregation/transport; lysosome/autolysosome for proteostasis; mitochondrial compartments for ROS/OXPHOS dysfunction; endothelial/pericyte interfaces at the BBB for Aβ transport (sighencea2024fromfundamentalsto pages 20-21, singh2024comprehensiveoverviewof pages 28-28, singh2024comprehensiveoverviewof pages 9-11).

Disease Progression (sequence of events)

• Early (preclinical): Aβ overproduction/under-clearance with subtle synaptic stress; rise of plasma/CSF p‑tau (pT181/pT217/pT231); microglial phenotype shifts near plaques; glucose hypometabolism in hippocampus/cortex (sighencea2024fromfundamentalsto pages 36-37, agnello2025fromamyloidto pages 1-2, singh2024comprehensiveoverviewof pages 9-11).
• Intermediate: Tau phosphorylation and local aggregation; prion-like tau propagation to connected regions; escalation of microglial inflammasome activity (IL‑1β), autophagy‑lysosomal dysfunction; mitochondrial ROS and metabolic failure; vascular/BBB leakage elevates protein burden (singh2024comprehensiveoverviewof pages 11-12, singh2024comprehensiveoverviewof pages 28-28, sighencea2024fromfundamentalsto pages 20-21, singh2024comprehensiveoverviewof pages 9-11).
• Symptomatic: Synapse loss correlates with cognitive decline; broader cortical involvement; neurodegeneration and clinical progression measurable by synaptic and neurodegeneration biomarkers (NfL) and cognitive trajectories (agnello2025fromamyloidto pages 1-2, sighencea2024fromfundamentalsto pages 36-37).

Phenotypic Manifestations (HP terms and links)

• Cognitive impairment and memory loss (HP:0002354), executive dysfunction; synaptic dysfunction (HP:0030753) closely aligned with biomarker and pathological synapse loss (agnello2025fromamyloidto pages 1-2, sighencea2024fromfundamentalsto pages 36-37).

Expert Opinions and Analysis

• Reframing AD beyond an amyloid-only model: integrated, multimodal pathways (amyloid, tau prion-like propagation, neuroinflammation, vascular/glymphatic, autophagy–lysosomal, mitochondrial) are jointly necessary to explain progression and to guide combination therapies and precision biomarker use (sighencea2024fromfundamentalsto pages 1-3, sighencea2024fromfundamentalsto pages 36-37).
• Microglial axes (APOE–TREM2) and inflammasomes (NLRP3/ASC) are major levers shaping local injury and clearance responses, offering therapeutic entry points; synaptic injury is the best correlate of cognition, reinforcing synaptic biomarkers as clinical endpoints (singh2024comprehensiveoverviewof pages 11-12, agnello2025fromamyloidto pages 1-2).
• Vascular/BBB and glymphatic pathways are nontrivial determinants of brain proteostasis and may partly explain variability in amyloid/tau accumulation and response to therapy (sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).

Current Applications and Real-World Implementations

• Anti‑amyloid monoclonal antibodies (aducanumab, lecanemab, donanemab) approved/studied with biomarker-driven selection (AT(N) frameworks including p‑tau and Aβ) and used to reduce plaques; reviews summarize 2023–2024 regulatory and clinical contexts (sighencea2024fromfundamentalsto pages 1-3, singh2024comprehensiveoverviewof pages 28-28).
• Biomarkers: Expanded ATX(N) frameworks incorporate synaptic/glial markers (e.g., SNAP‑25, GAP‑43, YKL‑40) measurable in CSF and increasingly plasma/exosomes, facilitating less invasive diagnosis and trial stratification (agnello2025fromamyloidto pages 1-2).
• Innate immunity targets: Preclinical/clinical exploration of TREM2‑modulating approaches and NLRP3 inhibitors aligns with microglial evidence (singh2024comprehensiveoverviewof pages 11-12).
• Clearance-centric strategies: Emphasis on BBB transporters (LRP1) and emerging interest in perivascular/glymphatic/meningeal lymphatic manipulation as adjuncts to immunotherapy (sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).

Relevant Statistics and Data from Recent Studies

• Vascular pathology: A review notes “92% of AD patients showing cerebral arteriosclerotic changes,” alongside mechanistic links to MEOX2/LRP and APOE4‑Cyclophilin‑A–MMP‑9 axes that impair CBF and BBB integrity (DOI: 10.3390/ijms252212311, 2024-11-16) (sighencea2024fromfundamentalsto pages 20-21).
• Early tau biomarkers: “Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages” supports diagnostic staging and trial enrichment (DOI: 10.3390/ijms252212311, 2024-11-16) (sighencea2024fromfundamentalsto pages 36-37).
• Mechanistic quotes (microglia/inflammation): A 2024 review synthesizes that Aβ/tau “activate inflammatory signaling in microglia and astrocytes,” implicating APOE ε4, TREM2, and NLRP3 inflammasomes as convergent risk and pathway nodes (DOI: 10.3390/ijms25136901, 2024-06) (singh2024comprehensiveoverviewof pages 11-12).

Gene/Protein Annotations (HGNC), Processes (GO), Phenotypes (HP), Cell Types (CL), Anatomy (UBERON), Chemicals (CHEBI)

• Genes/Proteins (HGNC): APP; PSEN1; PSEN2; APOE; TREM2; MAPT; NLRP3; PYCARD (ASC); LRP1 (singh2024comprehensiveoverviewof pages 2-3, singh2024comprehensiveoverviewof pages 11-12, sighencea2024fromfundamentalsto pages 20-21).
• Biological processes (GO): amyloid‑β metabolic process; tau protein phosphorylation/aggregate propagation; microglial activation; inflammasome assembly; autophagy/lysosomal degradation; insulin receptor signaling; response to oxidative stress; synaptic signaling (sighencea2024fromfundamentalsto pages 36-37, singh2024comprehensiveoverviewof pages 28-28, agnello2025fromamyloidto pages 1-2, singh2024comprehensiveoverviewof pages 2-3, singh2024comprehensiveoverviewof pages 11-12, singh2024comprehensiveoverviewof pages 9-11).
• Phenotypes (HP): memory impairment (HP:0002354); synaptic dysfunction (HP:0030753) (agnello2025fromamyloidto pages 1-2, sighencea2024fromfundamentalsto pages 36-37).
• Cell types (CL): neuron (CL:0000540); microglial cell (CL:0000122); astrocyte (CL:0000751); oligodendrocyte (CL:0000128); endothelial cell (CL:0000626); pericyte (cell ontology label) (singh2024comprehensiveoverviewof pages 11-12, sighencea2024fromfundamentalsto pages 20-21).
• Anatomy (UBERON): hippocampus (UBERON:0001890); cerebral cortex (UBERON:0000955); blood–brain barrier (UBERON:0002418); perivascular spaces; meningeal lymphatic vasculature (UBERON:0016880) (sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).
• Chemicals (CHEBI): amyloid‑β; tau; interleukin‑1β; reactive oxygen species (singh2024comprehensiveoverviewof pages 11-12, sighencea2024fromfundamentalsto pages 36-37).

Evidence Items with PMIDs/DOIs, URLs, Dates

• Sighencea et al., 2024 (review). From fundamentals to innovation in AD: molecular findings and therapies. DOI: 10.3390/ijms252212311; 2024-11-16. URL: https://doi.org/10.3390/ijms252212311 (amyloid/tau propagation; vascular/BBB/glymphatic; autophagy–lysosomal; approvals) (sighencea2024fromfundamentalsto pages 36-37, sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3).
• Singh et al., 2024 (review). Comprehensive overview of AD: etiological insights and degradation strategies. DOI: 10.3390/ijms25136901; 2024-06. URL: https://doi.org/10.3390/ijms25136901 (APP/secretases; microglial/inflammasome; autophagy–lysosomal; insulin/mitochondria) (singh2024comprehensiveoverviewof pages 28-28, singh2024comprehensiveoverviewof pages 2-3, singh2024comprehensiveoverviewof pages 11-12, singh2024comprehensiveoverviewof pages 9-11).
• Agnello et al., 2025 (review). From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights. DOI: 10.3390/cimb47080580; 2025-07. URL: https://doi.org/10.3390/cimb47080580 (synaptic biomarkers; ATX(N) expansion) (agnello2025fromamyloidto pages 1-2).

Limitations and Open Questions

• Quantitative performance metrics (e.g., synaptic biomarker AUCs, hazard ratios) require study-specific datasets. While multiple 2024–2025 reports provide such data, the cited reviews herein emphasize frameworks and mechanisms rather than pooled statistics (agnello2025fromamyloidto pages 1-2). Further integration with cohort-based analyses is warranted to operationalize thresholds and predictive values.

Conclusion

Recent (2023–2024) research reinforces AD as a systems-level disorder in which Aβ and tau pathology intersect with microglial innate immunity (APOE/TREM2), inflammasomes (NLRP3/ASC), proteostasis (autophagy–lysosomal), mitochondrial/oxidative stress, and neurovascular/glymphatic clearance. Early p‑tau shifts and synaptic biomarkers bridge preclinical pathology to clinical staging, while anti‑amyloid mAbs and emerging microglial/inflammasome/clearance-targeted strategies exemplify mechanism-informed translation. Ongoing work should integrate multi-omic, vascular/glymphatic, and synaptic endpoints to refine progression models and therapeutic combinations.

Citations: Sighencea 2024 (DOI: 10.3390/ijms252212311); Singh 2024 (DOI: 10.3390/ijms25136901); Agnello 2025 (DOI: 10.3390/cimb47080580). (sighencea2024fromfundamentalsto pages 36-37, singh2024comprehensiveoverviewof pages 28-28, agnello2025fromamyloidto pages 1-2, singh2024comprehensiveoverviewof pages 2-3, sighencea2024fromfundamentalsto pages 20-21, sighencea2024fromfundamentalsto pages 1-3, singh2024comprehensiveoverviewof pages 11-12, singh2024comprehensiveoverviewof pages 9-11)

References

1. (sighencea2024fromfundamentalsto pages 36-37): Mădălina Georgeta Sighencea, Ramona Ștefania Popescu, and Simona Corina Trifu. From fundamentals to innovation in alzheimer’s disease: molecular findings and revolutionary therapies. International Journal of Molecular Sciences, 25:12311, Nov 2024. URL: https://doi.org/10.3390/ijms252212311, doi:10.3390/ijms252212311. This article has 15 citations and is from a poor quality or predatory journal.

2. (sighencea2024fromfundamentalsto pages 1-3): Mădălina Georgeta Sighencea, Ramona Ștefania Popescu, and Simona Corina Trifu. From fundamentals to innovation in alzheimer’s disease: molecular findings and revolutionary therapies. International Journal of Molecular Sciences, 25:12311, Nov 2024. URL: https://doi.org/10.3390/ijms252212311, doi:10.3390/ijms252212311. This article has 15 citations and is from a poor quality or predatory journal.

3. (singh2024comprehensiveoverviewof pages 11-12): Manish Kumar Singh, Yoonhwa Shin, Songhyun Ju, Sunhee Han, Sung Soo Kim, and Insug Kang. Comprehensive overview of alzheimer’s disease: etiological insights and degradation strategies. International Journal of Molecular Sciences, 25:6901, Jun 2024. URL: https://doi.org/10.3390/ijms25136901, doi:10.3390/ijms25136901. This article has 33 citations and is from a poor quality or predatory journal.

4. (singh2024comprehensiveoverviewof pages 28-28): Manish Kumar Singh, Yoonhwa Shin, Songhyun Ju, Sunhee Han, Sung Soo Kim, and Insug Kang. Comprehensive overview of alzheimer’s disease: etiological insights and degradation strategies. International Journal of Molecular Sciences, 25:6901, Jun 2024. URL: https://doi.org/10.3390/ijms25136901, doi:10.3390/ijms25136901. This article has 33 citations and is from a poor quality or predatory journal.

5. (sighencea2024fromfundamentalsto pages 20-21): Mădălina Georgeta Sighencea, Ramona Ștefania Popescu, and Simona Corina Trifu. From fundamentals to innovation in alzheimer’s disease: molecular findings and revolutionary therapies. International Journal of Molecular Sciences, 25:12311, Nov 2024. URL: https://doi.org/10.3390/ijms252212311, doi:10.3390/ijms252212311. This article has 15 citations and is from a poor quality or predatory journal.

6. (singh2024comprehensiveoverviewof pages 9-11): Manish Kumar Singh, Yoonhwa Shin, Songhyun Ju, Sunhee Han, Sung Soo Kim, and Insug Kang. Comprehensive overview of alzheimer’s disease: etiological insights and degradation strategies. International Journal of Molecular Sciences, 25:6901, Jun 2024. URL: https://doi.org/10.3390/ijms25136901, doi:10.3390/ijms25136901. This article has 33 citations and is from a poor quality or predatory journal.

7. (singh2024comprehensiveoverviewof pages 2-3): Manish Kumar Singh, Yoonhwa Shin, Songhyun Ju, Sunhee Han, Sung Soo Kim, and Insug Kang. Comprehensive overview of alzheimer’s disease: etiological insights and degradation strategies. International Journal of Molecular Sciences, 25:6901, Jun 2024. URL: https://doi.org/10.3390/ijms25136901, doi:10.3390/ijms25136901. This article has 33 citations and is from a poor quality or predatory journal.

8. (agnello2025fromamyloidto pages 1-2): Luisa Agnello, Caterina Maria Gambino, Anna Maria Ciaccio, Francesco Cacciabaudo, Davide Massa, Anna Masucci, Martina Tamburello, Roberta Vassallo, Mauro Midiri, Concetta Scazzone, and Marcello Ciaccio. From amyloid to synaptic dysfunction: biomarker-driven insights into alzheimer’s disease. Current Issues in Molecular Biology, 47:580, Jul 2025. URL: https://doi.org/10.3390/cimb47080580, doi:10.3390/cimb47080580. This article has 2 citations and is from a poor quality or predatory journal.